vs
Apellis Pharmaceuticals, Inc.（APLS）与楼氏电子（KN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是楼氏电子的1.3倍（$199.9M vs $153.1M），楼氏电子净利率更高（6.3% vs -29.5%，领先35.8%），楼氏电子同比增速更快（22.7% vs -5.9%），楼氏电子自由现金流更多（$-3.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -13.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
楼氏电子是全球领先的微声学、音频处理及精密元件解决方案供应商，产品涵盖MEMS麦克风、平衡电枢扬声器、助听器组件、边缘音频处理芯片等，服务消费电子、汽车、医疗科技、工业等核心领域的全球客户。
APLS vs KN — 直观对比
营收规模更大
APLS
是对方的1.3倍
$153.1M
营收增速更快
KN
高出28.6%
-5.9%
净利率更高
KN
高出35.8%
-29.5%
自由现金流更多
KN
多$11.2M
$-14.3M
两年增速更快
APLS
近两年复合增速
-13.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $153.1M |
| 净利润 | $-59.0M | $9.7M |
| 毛利率 | — | 43.8% |
| 营业利润率 | -25.6% | 10.4% |
| 净利率 | -29.5% | 6.3% |
| 营收同比 | -5.9% | 22.7% |
| 净利润同比 | -62.2% | 585.0% |
| 每股收益（稀释后） | $-0.40 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSKN
| Q1 26 | — | $153.1M | ||
| Q4 25 | $199.9M | $162.2M | ||
| Q3 25 | $458.6M | $152.9M | ||
| Q2 25 | $178.5M | $145.9M | ||
| Q1 25 | $166.8M | $132.2M | ||
| Q4 24 | $212.5M | $142.5M | ||
| Q3 24 | $196.8M | $142.5M | ||
| Q2 24 | $199.7M | $204.7M |
净利润APLSKN
| Q1 26 | — | $9.7M | ||
| Q4 25 | $-59.0M | $21.0M | ||
| Q3 25 | $215.7M | $17.4M | ||
| Q2 25 | $-42.2M | $7.8M | ||
| Q1 25 | $-92.2M | $-2.0M | ||
| Q4 24 | $-36.4M | $18.5M | ||
| Q3 24 | $-57.4M | $500.0K | ||
| Q2 24 | $-37.7M | $-259.3M |
毛利率APLSKN
| Q1 26 | — | 43.8% | ||
| Q4 25 | — | 44.7% | ||
| Q3 25 | — | 45.7% | ||
| Q2 25 | — | 41.5% | ||
| Q1 25 | — | 40.3% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 44.1% | ||
| Q2 24 | — | 28.2% |
营业利润率APLSKN
| Q1 26 | — | 10.4% | ||
| Q4 25 | -25.6% | 15.9% | ||
| Q3 25 | 48.7% | 16.9% | ||
| Q2 25 | -18.6% | 10.1% | ||
| Q1 25 | -50.0% | 3.0% | ||
| Q4 24 | -12.3% | 10.8% | ||
| Q3 24 | -24.0% | 13.1% | ||
| Q2 24 | -14.7% | 6.2% |
净利率APLSKN
| Q1 26 | — | 6.3% | ||
| Q4 25 | -29.5% | 12.9% | ||
| Q3 25 | 47.0% | 11.4% | ||
| Q2 25 | -23.6% | 5.3% | ||
| Q1 25 | -55.3% | -1.5% | ||
| Q4 24 | -17.1% | 13.0% | ||
| Q3 24 | -29.2% | 0.4% | ||
| Q2 24 | -18.9% | -126.7% |
每股收益（稀释后）APLSKN
| Q1 26 | — | $0.13 | ||
| Q4 25 | $-0.40 | $0.23 | ||
| Q3 25 | $1.67 | $0.20 | ||
| Q2 25 | $-0.33 | $0.09 | ||
| Q1 25 | $-0.74 | $-0.02 | ||
| Q4 24 | $-0.30 | $0.20 | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $-2.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $41.0M |
| 总债务越低越好 | — | $131.0M |
| 股东权益账面价值 | $370.1M | $780.2M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资APLSKN
| Q1 26 | — | $41.0M | ||
| Q4 25 | $466.2M | $54.2M | ||
| Q3 25 | $479.2M | $92.5M | ||
| Q2 25 | $370.0M | $103.2M | ||
| Q1 25 | $358.4M | $101.9M | ||
| Q4 24 | $411.3M | $130.1M | ||
| Q3 24 | $396.9M | $92.6M | ||
| Q2 24 | $360.1M | $84.0M |
总债务APLSKN
| Q1 26 | — | $131.0M | ||
| Q4 25 | — | $114.0M | ||
| Q3 25 | — | $176.3M | ||
| Q2 25 | — | $190.0M | ||
| Q1 25 | — | $188.8M | ||
| Q4 24 | — | $202.5M | ||
| Q3 24 | — | $225.0M | ||
| Q2 24 | — | $261.2M |
股东权益APLSKN
| Q1 26 | — | $780.2M | ||
| Q4 25 | $370.1M | $775.8M | ||
| Q3 25 | $401.2M | $751.8M | ||
| Q2 25 | $156.3M | $746.1M | ||
| Q1 25 | $164.2M | $755.8M | ||
| Q4 24 | $228.5M | $756.0M | ||
| Q3 24 | $237.1M | $777.4M | ||
| Q2 24 | $264.3M | $753.0M |
总资产APLSKN
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B |
负债/权益比APLSKN
| Q1 26 | — | 0.17× | ||
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $0 |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-3.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -2.0% |
| 资本支出强度资本支出/营收 | 0.1% | 7.1% |
| 现金转化率经营现金流/净利润 | — | 0.00× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSKN
| Q1 26 | — | $0 | ||
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $29.1M | ||
| Q2 25 | $4.4M | $36.4M | ||
| Q1 25 | $-53.4M | $1.3M | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | $52.8M | ||
| Q2 24 | $-8.3M | $24.9M |
自由现金流APLSKN
| Q1 26 | — | $-3.1M | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $21.4M | ||
| Q2 25 | $4.4M | $31.3M | ||
| Q1 25 | $-53.4M | $-2.7M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $49.1M | ||
| Q2 24 | $-8.4M | $21.7M |
自由现金流率APLSKN
| Q1 26 | — | -2.0% | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 14.0% | ||
| Q2 25 | 2.5% | 21.5% | ||
| Q1 25 | -32.0% | -2.0% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 34.5% | ||
| Q2 24 | -4.2% | 10.6% |
资本支出强度APLSKN
| Q1 26 | — | 7.1% | ||
| Q4 25 | 0.1% | 9.4% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 2.6% | ||
| Q2 24 | 0.0% | 1.6% |
现金转化率APLSKN
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.67× | ||
| Q2 25 | — | 4.67× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 105.60× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
KN
暂无分部数据
